Skip to Content
Merck
  • Regulated degradation of HMG CoA reductase requires conformational changes in sterol-sensing domain.

Regulated degradation of HMG CoA reductase requires conformational changes in sterol-sensing domain.

Nature communications (2022-07-26)
Hongwen Chen, Xiaofeng Qi, Rebecca A Faulkner, Marc M Schumacher, Linda M Donnelly, Russell A DeBose-Boyd, Xiaochun Li
ABSTRACT

3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is the rate-limiting enzyme in cholesterol synthesis and target of cholesterol-lowering statin drugs. Accumulation of sterols in endoplasmic reticulum (ER) membranes accelerates degradation of HMGCR, slowing the synthesis of cholesterol. Degradation of HMGCR is inhibited by its binding to UBIAD1 (UbiA prenyltransferase domain-containing protein-1). This inhibition contributes to statin-induced accumulation of HMGCR, which limits their cholesterol-lowering effects. Here, we report cryo-electron microscopy structures of the HMGCR-UBIAD1 complex, which is maintained by interactions between transmembrane helix (TM) 7 of HMGCR and TMs 2-4 of UBIAD1. Disrupting this interface by mutagenesis prevents complex formation, enhancing HMGCR degradation. TMs 2-6 of HMGCR contain a 170-amino acid sterol sensing domain (SSD), which exists in two conformations-one of which is essential for degradation. Thus, our data supports a model that rearrangement of the TMs in the SSD permits recruitment of proteins that initate HMGCR degradation, a key reaction in the regulatory system that governs cholesterol synthesis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-c-Myc antibody, Mouse monoclonal, clone 9E10, purified from hybridoma cell culture
Roche
cOmplete, Mini Protease Inhibitor Cocktail, Tablets provided in EASYpacks
Millipore
ANTI-FLAG® M2 Affinity Gel, purified immunoglobulin, buffered aqueous glycerol solution
Millipore
T7•Tag® Antibody Agarose